DRUG Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to Bright Minds Biosciences's net margin of 11.99%. Bright Minds Biosciences's return on equity of -- beat Johnson & Johnson's return on equity of 20.88%.

Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.71%. Given that Johnson & Johnson has higher upside potential than Bright Minds Biosciences, analysts believe Johnson & Johnson is more attractive than Bright Minds Biosciences.

Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.34% to investors and pays a quarterly dividend of $1.24 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bright Minds Biosciences quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Bright Minds Biosciences's net income of $168K is lower than Johnson & Johnson's net income of $2.7B. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 4.03x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of -49.65%. Bright Minds Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Bright Minds Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Bright Minds Biosciences.

Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Bright Minds Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bright Minds Biosciences's net income of $168K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Bright Minds Biosciences's net margin of -2357.27%. Bright Minds Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.

Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Bright Minds Biosciences, analysts believe Palatin Technologies is more attractive than Bright Minds Biosciences.

Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Bright Minds Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Bright Minds Biosciences's net income of $168K is higher than Palatin Technologies's net income of -$7.8M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.

Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5627.85%. Given that Theriva Biologics has higher upside potential than Bright Minds Biosciences, analysts believe Theriva Biologics is more attractive than Bright Minds Biosciences.

Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Bright Minds Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bright Minds Biosciences's net income of $168K is higher than Theriva Biologics's net income of -$7.7M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.